Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec-dzkt)
## Overview
Durveqtix is an adeno-associated virus vector-based gene therapy designed to deliver a functional copy of the *F9* gene to hepatocytes. It enables endogenous production of Factor IX (FIX) in patients with Hemophilia B, potentially eliminating the need for routine prophylactic factor replacement therapy. It is administered as a single-dose intravenous infusion.
## Primary Indications
Treatment of adults (18 years or older) with moderately severe to severe Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
## Adult Dosing
The recommended dose is 5 x 10¹¹ vector genomes per kilogram (vg/kg) of body weight, administered as a single intravenous infusion.
## Pediatric Dosing
Safety and effectiveness in pediatric patients (younger than 18 years) have not been established. Use in this population is not currently approved.
## Dose Adjustments
There are no dose adjustments for renal or hepatic impairment provided in the labeling, as this is a one-time gene therapy. However, baseline liver function tests (LFTs) must be normal to proceed with administration.
## Contraindications
* Known hypersensitivity to fidanacogene elaparvovec-dzkt or any of its components.
* Active, acute, or chronic infections (e.g., HBV, HCV, HIV) that could be exacerbated by the transient immunosuppression required for treatment.
## Adverse Effects
* **Common:** Infusion-related reactions (nausea, fatigue, pyrexia, headache), elevated liver aminotransferases (ALT), and cytokine release syndrome.
* **Serious:** Hepatotoxicity (frequently requiring corticosteroid management), potential risk of malignancy due to vector integration (theoretical), and immune-mediated clearance of hepatocytes expressing the transgene.
## Key Drug Interactions
The primary interaction is the necessity for prophylactic systemic corticosteroids. Patients will undergo a tapering course of prednisolone (or equivalent) to manage immune responses to the viral vector and subsequent hepatic injury. Avoid hepatotoxic medications or those that may increase bleeding risk during the immunosuppressive phase.
## Monitoring
* **Pre-treatment:** Baseline LFTs (ALT/AST, bilirubin, alkaline phosphatase) and screen for anti-AAVRh74 capsid antibodies.
* **Post-treatment:** Weekly monitoring of ALT levels for at least 12 weeks post-infusion to detect and manage immune-mediated hepatotoxicity.
* **Long-term:** Monitor Factor IX activity levels periodically to ensure therapeutic range and observe for long-term safety, including malignancy.
## Clinical Pearls
* **Immune Management:** Prepare for a mandatory course of corticosteroids starting before infusion to prevent a decline in FIX activity levels caused by T-cell mediated destruction of transduced hepatocytes.
* **Efficacy Lag:** FIX activity levels may take several weeks to stabilize; patients may require supplemental prophylaxis transition during the early post-infusion period.
* **Patient Counseling:** Advise patients that the therapy is permanent, but its long-term durability is still being studied. Ensure patients understand the need for strict adherence to the corticosteroid taper to protect the gene therapy product.
* **Handling:** Product must be handled under strict sterile conditions; follow institutional guidelines for the management of biological products and gene therapy disposal.
***
**Educational Disclaimer:** This information is for educational purposes only. Gene therapy protocols are rapidly evolving and highly specialized. Always consult the official FDA-approved package insert (Label) and your institution's specific clinical guidelines and pharmacy protocols before prescribing or administering.
